{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:46:33Z","timestamp":1792172793914,"version":"4.4.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":449,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"British Oncology Pharmacy Association-Pharmacy Research UK","award":["BOPA_PRUK-2021-3-CJ"],"award-info":[{"award-number":["BOPA_PRUK-2021-3-CJ"]}]},{"name":"UCL Graduate Research Scholarship"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We aim to evaluate change in the use of prognostic guideline-directed medical therapies (GDMTs) for heart failure (HF) before and after a cancer diagnosis as well as the matched non-cancer controls, including renin-angiotensin-system inhibitors (RASIs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a longitudinal study in patients with HF in the UK Clinical Practice Research Datalink between 2005 and 2021. We selected patients with probable HF with reduced ejection fraction (HFrEF) based on diagnostic and prescription records. We described the longitudinal trends in the use and dosing of GDMTs before and after receiving an incident cancer diagnosis. HF patients with cancer were matched with a 1:1 ratio to HF patients without cancer to investigate the association between cancer diagnosis and treatment adherence, persistence, initiation, and dose titration as odds ratios (ORs) with 95% confidence intervals (CIs) using multivariable logistic regression models. Of 8504 eligible HFrEF patients with incident cancer, 4890 were matched to controls without cancer. The mean age was 75.7 (\u00b18.4) years and 73.9% were male. In the 12 months following a cancer diagnosis, patients experienced reductions in the use and dosing of GDMT. Compared with the non-cancer controls, patients with cancer had higher risks for poor adherence for all three medication classes (RASIs: OR = 1.51, 95% CI = 1.35\u20131.68; beta-blockers: OR = 1.22, 95% CI = 1.08\u20131.37; MRAs: OR = 1.31, 95% CI = 1.08\u20131.59) and poor persistence (RASIs: OR = 2.04, 95% CI = 1.75\u20132.37; beta-blockers: OR = 1.35, 95% CI = 1.12\u20131.63; MRAs: OR = 1.49, 95% CI = 1.16\u20131.93), and higher risks for dose down-titration for RASIs (OR = 1.69, 95% CI = 1.40\u20132.04) and beta-blockers (OR = 1.31, 95% CI = 1.05\u20131.62). Cancer diagnosis was not associated with treatment initiation or dose up-titration. Event rates for HF hospitalization and mortality were higher in patients with poor adherence or persistence to GDMTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following a cancer diagnosis, patients with HFrEF were more likely to have reduced use of GDMTs for HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14981","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T06:57:51Z","timestamp":1721717871000},"page":"3911-3923","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of Heart Failure Medical Therapy Before and After a Cancer Diagnosis: A Longitudinal Study"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-6262","authenticated-orcid":false,"given":"Chengsheng","family":"Ju","sequence":"first","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallis C.Y.","family":"Lau","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy, University College London , London ,","place":["UK"]},{"name":"Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust , London ,","place":["UK"]},{"name":"Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park , Hong Kong, SAR ,","place":["China"]},{"name":"Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong , Hong Kong, SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Manisty","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College London , London ,","place":["UK"]},{"name":"Department of Cardiology, St Bartholomew's Hospital, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkie","family":"Chambers","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy, University College London , London ,","place":["UK"]},{"name":"Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brauer","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy, University College London , London ,","place":["UK"]},{"name":"Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla S.","family":"Mackenzie","sequence":"additional","affiliation":[{"name":"MEMO Research, Division of Molecular and Clinical Medicine, University of Dundee , Dundee ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-7267","authenticated-orcid":false,"given":"Li","family":"Wei","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy, University College London , London ,","place":["UK"]},{"name":"Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust , London ,","place":["UK"]},{"name":"Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park , Hong Kong, SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2026012113124233500_ehf214981-bib-0001","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"2026012113124233500_ehf214981-bib-0002","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead073","article-title":"Association between heart failure and the incidence of cancer: A systematic review and meta-analysis","volume":"3","author":"Jaiswal","year":"2023","journal-title":"Eur Heart J Open"},{"key":"2026012113124233500_ehf214981-bib-0003","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026012113124233500_ehf214981-bib-0004","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026012113124233500_ehf214981-bib-0005","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026012113124233500_ehf214981-bib-0006","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: A long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0007","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: Associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0008","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113124233500_ehf214981-bib-0009","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113124233500_ehf214981-bib-0010","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0011","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","article-title":"Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"key":"2026012113124233500_ehf214981-bib-0012","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1161\/CIRCRESAHA.121.318223","article-title":"Heart failure with targeted cancer therapies: Mechanisms and cardioprotection","volume":"128","author":"Hahn","year":"2021","journal-title":"Circ Res"},{"key":"2026012113124233500_ehf214981-bib-0013","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"2026012113124233500_ehf214981-bib-0014","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.cir.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"2026012113124233500_ehf214981-bib-0015","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/01.cir.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2026012113124233500_ehf214981-bib-0016","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1751-7133.2011.00250.x","article-title":"Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: Findings from IMPROVE HF","volume":"18","author":"Gheorghiade","year":"2012","journal-title":"Congest Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0017","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012113124233500_ehf214981-bib-0018","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026012113124233500_ehf214981-bib-0019","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113124233500_ehf214981-bib-0020","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): A population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026012113124233500_ehf214981-bib-0021","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11912-020-00990-z","article-title":"Cancer risk in the heart failure population: Epidemiology, mechanisms, and clinical implications","volume":"23","author":"Cuomo","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"2026012113124233500_ehf214981-bib-0022","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/ije\/dys188","article-title":"Data resource profile: Cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER)","volume":"41","author":"Denaxas","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2026012113124233500_ehf214981-bib-0023","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2026012113124233500_ehf214981-bib-0024","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2026012113124233500_ehf214981-bib-0025","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"2026012113124233500_ehf214981-bib-0026","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/CLEP.S251710","article-title":"Identification of patients with new-onset heart failure and reduced ejection fraction in Danish administrative registers","volume":"12","author":"Madelaire","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2026012113124233500_ehf214981-bib-0027","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: From physician's prescriptions to patient's dispensations, medication adherence and persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0028","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1186\/s12885-018-4947-8","article-title":"Statin use in cancer survivors versus the general population: Cohort study using primary care data from the UK clinical practice research datalink","volume":"18","author":"Chidwick","year":"2018","journal-title":"BMC Cancer"},{"key":"2026012113124233500_ehf214981-bib-0029","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/afw039","article-title":"Development and validation of an electronic frailty index using routine primary care electronic health record data","volume":"45","author":"Clegg","year":"2016","journal-title":"Age Ageing"},{"key":"2026012113124233500_ehf214981-bib-0030","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ahj.2021.01.017","article-title":"Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities","volume":"235","author":"Albert","year":"2021","journal-title":"Am Heart J"},{"key":"2026012113124233500_ehf214981-bib-0031","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2215\/CJN.14180920","article-title":"Management of heart failure patient with CKD","volume":"16","author":"Banerjee","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012113124233500_ehf214981-bib-0032","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction - Opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101596","article-title":"Management of heart failure with reduced ejection fraction","volume":"48","author":"Rashid","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2026012113124233500_ehf214981-bib-0034","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023-5-6","article-title":"Optimization of GDMT for patients with heart failure and reduced ejection fraction: Can physiological and biological barriers explain the gaps in adherence to heart failure guidelines?","volume":"12","author":"Jarjour","year":"2023","journal-title":"Drugs in Context"},{"key":"2026012113124233500_ehf214981-bib-0035","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: A population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"key":"2026012113124233500_ehf214981-bib-0036","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012113124233500_ehf214981-bib-0037","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the cardio-oncology study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0038","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026012113124233500_ehf214981-bib-0039","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113124233500_ehf214981-bib-0040","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012113124233500_ehf214981-bib-0041","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/ejhf.2818","article-title":"Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials","volume":"25","author":"Dobbin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0042","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ejhf.2207","article-title":"The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative","volume":"23","author":"Leedy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0043","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/clc.22917","article-title":"Sex differences in heart failure","volume":"41","author":"Eisenberg","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026012113124233500_ehf214981-bib-0044","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: Population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"2026012113124233500_ehf214981-bib-0045","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012113124233500_ehf214981-bib-0046","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0047","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113124233500_ehf214981-bib-0048","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: Cancer development in patients with cardiovascular disease","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012113124233500_ehf214981-bib-0049","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","article-title":"Accelerated and personalized therapy for heart failure with reduced ejection fraction","volume":"43","author":"Shen","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113124233500_ehf214981-bib-0050","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3911\/64517201\/eschf_11_6_3911.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3911\/64517201\/eschf_11_6_3911.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:46Z","timestamp":1769019286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/3911\/8269409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,23]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14981","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"2023-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}